Singh Darshan, Müller Christian P, Vicknasingam Balasingam K
Centre for Drug Research, Universiti Sains Malaysia, 11800 Minden, Penang, Malaysia.
Department of Psychiatry and Psychotherapy, University Clinic, Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany.
Drug Alcohol Depend. 2014 Jun 1;139:132-7. doi: 10.1016/j.drugalcdep.2014.03.017. Epub 2014 Mar 22.
Kratom (Mitragyna speciosa) preparations have been traditionally used in Southeast Asia for its medicinal properties. Lately, Kratom use has spread to Europe and the US, where abuse potential and health hazards increasingly emerge. This study is the first to measure systematically Kratom dependence, withdrawal symptoms, and drug craving in regular Kratom users in Malaysia.
A cross-sectional survey of 293 regular Kratom users was conducted in the community across three northern peninsular states of Malaysia. The Leeds Dependence Questionnaire, Marijuana Withdrawal Checklist, and Marijuana Craving Questionnaire-Short Form were used to measure Kratom dependence, withdrawal and craving.
More than half of the regular users (>6 month of use) developed severe Kratom dependence problems, while 45% showed a moderate Kratom dependence. Physical withdrawal symptoms commonly experienced include muscle spasms and pain, sleeping difficulty, watery eyes/nose, hot flashes, fever, decreased appetite, and diarrhoea. Psychological withdrawal symptoms commonly reported were restlessness, tension, anger, sadness, and nervousness. The average amount of the psychoactive compound, mitragynine, in a single dose of a Kratom drink was 79mg, suggesting an average daily intake of 276.5mg. Regular users who consumed ≥3 glasses Kratom per day, had higher odds of developing severe Kratom dependence, withdrawal symptoms, and inability to control Kratom craving.
The findings from this study show that regular Kratom use is associated with drug dependency, development of withdrawal symptoms, and craving. These symptoms become more severe with prolonged use and suggest a stronger control of the drug.
在东南亚,人们传统上一直使用柯拉托姆(Mitragyna speciosa)制剂来发挥其药用特性。最近,柯拉托姆的使用已蔓延到欧洲和美国,在这些地方,其滥用可能性和健康危害日益显现。本研究首次系统测量了马来西亚柯拉托姆经常使用者的药物依赖、戒断症状和药物渴望。
在马来西亚半岛北部三个州的社区对293名柯拉托姆经常使用者进行了横断面调查。使用利兹依赖问卷、大麻戒断清单和大麻渴望问卷简表来测量柯拉托姆的依赖、戒断和渴望情况。
超过一半的经常使用者(使用超过6个月)出现了严重的柯拉托姆依赖问题,而45%表现出中度的柯拉托姆依赖。常见的身体戒断症状包括肌肉痉挛和疼痛、睡眠困难、流泪/流鼻涕、潮热、发烧、食欲下降和腹泻。常见的心理戒断症状包括烦躁不安、紧张、愤怒、悲伤和紧张。一剂柯拉托姆饮料中精神活性化合物帽柱木碱的平均含量为79毫克,这表明平均每日摄入量为276.5毫克。每天饮用≥3杯柯拉托姆的经常使用者出现严重柯拉托姆依赖、戒断症状和无法控制柯拉托姆渴望的几率更高。
本研究结果表明,经常使用柯拉托姆与药物依赖、戒断症状的出现以及渴望有关。随着使用时间延长,这些症状会变得更加严重,这表明需要对该药物进行更严格的管控。